
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

BlossomHill Therapeutics, Inc.

(Name of Issuer)

Common Stock, \$0.0001 par value per share

(Title of Class of Securities)

(CUSIP Number)

Neb Obradovic
Cormorant Asset Management, LP, 200 Clarendon Street, 50th Floor
Boston, MA, 02116
857-702-0386

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

08/06/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No.

Name of reporting person

1
Cormorant Global Healthcare Master Fund, LP

Check the appropriate box if a member of a Group (See Instructions)

2
☐ (a)
☒ (b)

3
SEC use only

4	Source of funds (See Instructions)
	WC
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
	☐
6	Citizenship or place of organization
	CAYMAN ISLANDS
	Sole Voting Power
7	0.00
Number of Shares Beneficially Owned by Each Reporting Person With:	Shared Voting Power
8	959,090.00
	Sole Dispositive Power
9	0.00
	Shared Dispositive Power
10	959,090.00
	Aggregate amount beneficially owned by each reporting person
11	959,090.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
	☐
13	Percent of class represented by amount in Row (11)
	3.13 %
14	Type of Reporting Person (See Instructions)
	PN

SCHEDULE 13D

CUSIP No.

1	Name of reporting person
	Cormorant Global Healthcare GP, LLC
	Check the appropriate box if a member of a Group (See Instructions)
2	☐ (a)
	☒ (b)
3	SEC use only
4	Source of funds (See Instructions)
	AF
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
	☐
6	Citizenship or place of organization
	DELAWARE
Number of Shares Beneficially Owned by	Sole Voting Power
7	0.00
8	Shared Voting Power

Each Reporting Person With:	959,090.00
	Sole Dispositive Power
9	0.00
	Shared Dispositive Power
10	959,090.00
	Aggregate amount beneficially owned by each reporting person
11	959,090.00
	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
12	☐
	Percent of class represented by amount in Row (11)
13	3.13 %
	Type of Reporting Person (See Instructions)
14	OO

SCHEDULE 13D

CUSIP No.

	Name of reporting person
1	Cormorant Private Healthcare Fund III, LP
	Check the appropriate box if a member of a Group (See Instructions)
2	☐ (a)
	☒ (b)
3	SEC use only
	Source of funds (See Instructions)
4	WC
	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
5	☐
	Citizenship or place of organization
6	DELAWARE
	Sole Voting Power
7	0.00
	Shared Voting Power
8	1,228,315.00
	Sole Dispositive Power
9	0.00
	Shared Dispositive Power
10	1,228,315.00
	Aggregate amount beneficially owned by each reporting person
11	1,228,315.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

	☐	Percent of class represented by amount in Row (11)
13		4.01 %
		Type of Reporting Person (See Instructions)
14		PN

SCHEDULE 13D

CUSIP No.

	Name of reporting person	
1	Cormorant Private Healthcare GP III, LLC	
	Check the appropriate box if a member of a Group (See Instructions)	
2	☐ (a)	
	☒ (b)	
3	SEC use only	
	Source of funds (See Instructions)	
4	AF	
	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)	
5	☐	
	Citizenship or place of organization	
6	DELAWARE	
	Sole Voting Power	
7	0.00	
	Shared Voting Power	
8	1,228,315.00	
	Sole Dispositive Power	
9	0.00	
	Shared Dispositive Power	
10	1,228,315.00	
	Aggregate amount beneficially owned by each reporting person	
11	1,228,315.00	
	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)	
12	☐	
	Percent of class represented by amount in Row (11)	
13	4.01 %	
	Type of Reporting Person (See Instructions)	
14	OO	

SCHEDULE 13D

CUSIP No.

1	Name of reporting person
	Cormorant Private Healthcare Fund V, LP
	Check the appropriate box if a member of a Group (See Instructions)
2	☐ (a)
	☒ (b)
3	SEC use only
4	Source of funds (See Instructions)
	WC
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
	☐
6	Citizenship or place of organization
	DELAWARE
	Sole Voting Power
7	0.00
Number of	Shared Voting Power
Shares	
Beneficially	8
Owned by	1,052,460.00
Each	Sole Dispositive Power
Reporting	9
Person	0.00
With:	Shared Dispositive Power
	10
	1,052,460.00
11	Aggregate amount beneficially owned by each reporting person
	1,052,460.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
	☐
13	Percent of class represented by amount in Row (11)
	3.43 %
14	Type of Reporting Person (See Instructions)
	PN

SCHEDULE 13D**CUSIP No.**

1	Name of reporting person
	Cormorant Private Healthcare GP V, LLC
	Check the appropriate box if a member of a Group (See Instructions)
2	☐ (a)
	☒ (b)
3	SEC use only
4	Source of funds (See Instructions)

	AF
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
	☐
6	Citizenship or place of organization
	DELAWARE
	Sole Voting Power
7	0.00
Number of Shares Beneficially Owned by Each Reporting Person With:	Shared Voting Power
8	1,052,460.00
	Sole Dispositive Power
9	0.00
	Shared Dispositive Power
10	1,052,460.00
11	Aggregate amount beneficially owned by each reporting person
	1,052,460.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
	☐
13	Percent of class represented by amount in Row (11)
	3.43 %
14	Type of Reporting Person (See Instructions)
	OO

SCHEDULE 13D

CUSIP No.

1	Name of reporting person
	Cormorant Private Healthcare Fund VI, LP
	Check the appropriate box if a member of a Group (See Instructions)
2	☐ (a)
	☒ (b)
3	SEC use only
4	Source of funds (See Instructions)
	WC
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
	☐
6	Citizenship or place of organization
	DELAWARE
Number of Shares Beneficially Owned by Each Reporting	Sole Voting Power
7	0.00
	Shared Voting Power
8	374,169.00

Person With:	9	Sole Dispositive Power
		0.00
		Shared Dispositive Power
	10	374,169.00
		Aggregate amount beneficially owned by each reporting person
11		374,169.00
		Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
12		☐
		Percent of class represented by amount in Row (11)
13		1.22 %
		Type of Reporting Person (See Instructions)
14		PN

SCHEDULE 13D

CUSIP No.

		Name of reporting person
1		Cormorant Private Healthcare GP VI, LLC
		Check the appropriate box if a member of a Group (See Instructions)
2		☐ (a)
		☒ (b)
3		SEC use only
		Source of funds (See Instructions)
4		AF
		Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
5		☐
		Citizenship or place of organization
6		DELAWARE
		Sole Voting Power
	7	0.00
		Shared Voting Power
	8	374,169.00
		Sole Dispositive Power
	9	0.00
		Shared Dispositive Power
	10	374,169.00
		Aggregate amount beneficially owned by each reporting person
11		374,169.00
		Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
12		☐
		Percent of class represented by amount in Row (11)
13		

1.22 %
Type of Reporting Person (See Instructions)
14
OO

SCHEDULE 13D

CUSIP No.

1 Name of reporting person
Cormorant Asset Management, LP
Check the appropriate box if a member of a Group (See Instructions)
2 ☐ (a)
☒ (b)
3 SEC use only
4 Source of funds (See Instructions)
AF
5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
☐
6 Citizenship or place of organization
DELAWARE
7 Sole Voting Power
0.00
Number of Shares Beneficially Owned by Each Reporting Person With: 8 Shared Voting Power
3,614,034.00
9 Sole Dispositive Power
0.00
10 Shared Dispositive Power
3,614,034.00
11 Aggregate amount beneficially owned by each reporting person
3,614,034.00
12 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
☐
13 Percent of class represented by amount in Row (11)
11.79 %
14 Type of Reporting Person (See Instructions)
IA, PN

SCHEDULE 13D

CUSIP No.

1 Name of reporting person
Chen Bihua
Check the appropriate box if a member of a Group (See Instructions)

2 ☐ (a)
☒ (b)

3 SEC use only
Source of funds (See Instructions)

4 AF
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5 ☐
Citizenship or place of organization

6 UNITED STATES
Sole Voting Power

7 1,328.00
Number of Shares Beneficially Owned by Each Reporting Person With: Shared Voting Power

8 3,614,034.00
Sole Dispositive Power

9 1,328.00
Shared Dispositive Power

10 3,614,034.00
Aggregate amount beneficially owned by each reporting person

11 3,615,362.00
Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12 ☐
Percent of class represented by amount in Row (11)

13 11.8 %
Type of Reporting Person (See Instructions)

14 IN

SCHEDULE 13D

Item 1. Security and Issuer

Title of Class of Securities:

(a)

Common Stock, \$0.0001 par value per share

Name of Issuer:

(b)

BlossomHill Therapeutics, Inc.

Address of Issuer's Principal Executive Offices:

(c)

10255 Science Center Drive, Suite 200, San Diego, CALIFORNIA , 92121.

Item 2. Identity and Background

(a)

Cormorant Global Healthcare Master Fund, LP Cormorant Global Healthcare GP, LLC Cormorant Private Healthcare Fund III, LP Cormorant Private Healthcare GP III, LLC Cormorant Private Healthcare Fund V, LP Cormorant Private

Healthcare GP V, LLC Cormorant Private Healthcare Fund VI, LP Cormorant Private Healthcare GP VI, LLC
Cormorant Asset Management, LP Bihua Chen

(b) 200 Clarendon Street, 50th Floor Boston, MA 02116

The principal business of the Reporting Persons, other than Bihua Chen, is investing in securities and providing investment management services. Bihua Chen serves as the managing member of the general partners of the

(c) investment funds identified in Item 2(a) and of Cormorant Asset Management GP, LLC, the general partner of Cormorant Asset Management, LP, which serves as investment manager to such funds. Bihua Chen is also a director of the Issuer.

(d) None of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e) None of the Reporting Persons has, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or State securities laws or finding any violation with respect to such laws.

(f) Cormorant Global Healthcare Master Fund, LP - Cayman Islands Cormorant Global Healthcare GP, LLC - Delaware
Cormorant Private Healthcare Fund III, LP - Delaware Cormorant Private Healthcare GP III, LLC - Delaware
Cormorant Private Healthcare Fund V, LP - Delaware Cormorant Private Healthcare GP V, LLC - Delaware
Cormorant Private Healthcare Fund VI, LP - Delaware Cormorant Private Healthcare GP VI, LLC - Delaware
Cormorant Asset Management, LP - Delaware Bihua Chen - United States

Item 3. Source and Amount of Funds or Other Consideration

Of the Common Stock reported herein as being beneficially owned by the Reporting Persons, 1,599,993 and 1,701,541 shares were issued upon the automatic conversion of shares of Series A Preferred Stock and Series B Preferred Stock, respectively, upon the closing of the Issuer's initial public offering on August 10, 2026. The shares of Series A Preferred Stock and Series B Preferred Stock were purchased in private sales for approximately \$49,999,990.59 using working capital of the Reporting Persons. The remaining 312,500 shares of Common Stock were purchased from the underwriters of the Issuer's initial public offering in connection with such offering for aggregate consideration of \$5,000,000 (as reported in Item 5 below), the consideration for which was paid using working capital of the Reporting Persons. In addition, Bihua Chen was granted a stock option to purchase up to 23,904 shares of Common Stock at a price of \$16.00 per share for her service as a director of the Issuer, which option vests in equal monthly installments over three years from the August 6, 2026 date of grant.

Item 4. Purpose of Transaction

The Reporting Persons acquired the securities reported herein for the benefit of the above-referenced private investment funds and accounts for investment purposes. The Reporting Persons intend to evaluate this investment in the Issuer and options with respect to such investment on an ongoing basis. The Reporting Persons may acquire additional Common Stock of the Issuer from time to time or may dispose of any or all of such Common Stock or other securities held or beneficially owned by them at any time. From time to time, the Reporting Persons may engage in discussions with the Issuer's Board of Directors and/or members of the Issuer's management team concerning, without limitation, potential business combinations and strategic alternatives, the business, operations, capital structure, governance, management, strategy of the Issuer and other matters concerning the Issuer. The Reporting Persons reserve the right to change their purpose and to formulate and implement plans or proposals with respect to the Issuer at any time and from time to time. Any such action may be made by the Reporting Persons alone or in conjunction with other shareholders, potential acquirers, financing sources and/or other third parties and could include one or more purposes, plans or proposals that relate to or would result in actions required to be reported herein in accordance with Item 4 of Schedule 13D. Bihua Chen, who serves as the manager of Cormorant Asset Management, LP, Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare GP III, LLC, Cormorant Private Healthcare GP V, LLC and Cormorant Private Healthcare GP VI, LLC, is a director of the Issuer.

Item 5. Interest in Securities of the Issuer

(a) See Items 7-13 of the cover page and Item 2.

See Items 7-13 of the cover page and Item 2. The percentages reported herein with respect to the Reporting Persons' holdings are calculated based upon 30,643,660 shares of Common Stock outstanding following the closing of the Issuer's initial public offering, as reported in the Prospectus filed by the Issuer on August 7, 2026. The shares reported for Bihua Chen include 1,328 shares of Common Stock that she has the right to receive within 60 days upon the exercise of a stock option to purchase 21,248 shares of Common Stock granted to her in her capacity as a director of the Issuer.

(c) On August 10, 2026, Cormorant Global Healthcare Master Fund, LP acquired 312,500 shares of Common Stock in the Issuer's initial public offering at a price of \$16.00 per share.

(d) Not applicable.

(e) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

In connection with their purchase of Series A Preferred Stock and Series B Preferred Stock, the Reporting Persons have certain rights with respect to the registration under the Securities Act of 1933, as amended, of Common Stock held by the Reporting Persons, pursuant to the Third Amended and Restated Investor Rights Agreement, dated as of December 28, 2023 (the "Investor Rights Agreement"), by and among the Issuer and the investors named therein. These rights include demand registration rights, Form S-3 registration rights and piggyback registration rights. This

summary is qualified in its entirety by reference to the Investor Rights Agreement, which is incorporated by reference herein.

Item 7. Material to be Filed as Exhibits.

Exhibit 99.1 Joint Filing Agreement, by and among the Reporting Persons. Exhibit 99.2 Third Amended and Restated Investor Rights Agreement, dated as of December 28, 2023, by and among the Issuer and the investors named therein (incorporated by reference to Exhibit 4.2 to the Issuer's Registration Statement on Form S-1).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Cormorant Global Healthcare Master Fund, LP

Signature: /s/ CORMORANT GLOBAL HEALTHCARE
MASTER FUND, LP By: Cormorant Global
Healthcare GP, LLC, its General Partner

Name/Title: By: Bihua Chen, Managing Member

Date: 08/13/2026

Cormorant Global Healthcare GP, LLC

Signature: /s/ Bihua Chen

Name/Title: By: Bihua Chen, Managing Member

Date: 08/13/2026

Cormorant Private Healthcare Fund III, LP

Signature: /s/ CORMORANT PRIVATE HEALTHCARE
FUND III, LP By: Cormorant Private Healthcare
GP III, LLC, its General Partner

Name/Title: By: Bihua Chen, Managing Member

Date: 08/13/2026

Cormorant Private Healthcare GP III, LLC

Signature: /s/ Bihua Chen

Name/Title: By: Bihua Chen, Managing Member

Date: 08/13/2026

Cormorant Private Healthcare Fund V, LP

Signature: /s/ CORMORANT PRIVATE HEALTHCARE
FUND V, LP By: Cormorant Private Healthcare
GP V, LLC, its General Partner

Name/Title: By: Bihua Chen, Managing Member

Date: 08/13/2026

Cormorant Private Healthcare GP V, LLC

Signature: /s/ Bihua Chen

Name/Title: By: Bihua Chen, Managing Member

Date: 08/13/2026

Cormorant Private Healthcare Fund VI, LP

Signature: /s/ CORMORANT PRIVATE HEALTHCARE
FUND VI, LP By: Cormorant Private Healthcare
GP VI, LLC, its General Partner

Name/Title: By: Bihua Chen, Managing Member

Date: 08/13/2026

Cormorant Private Healthcare GP VI, LLC

Signature: /s/ Bihua Chen

Name/Title: By: Bihua Chen, Managing Member

Date: 08/13/2026

Cormorant Asset Management, LP

/s/ CORMORANT ASSET MANAGEMENT, LP
Signature: By: Cormorant Asset Management GP, LLC, its
General Partner

Name/Title: By: Bihua Chen, Managing Member

Date: 08/13/2026

Chen Bihua

Signature: /s/ Bihua Chen

Name/Title: Bihua Chen

Date: 08/13/2026

JOINT FILING AGREEMENT

This Joint Filing Agreement, dated as of August 13, 2026, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare Fund III, LP, Cormorant Private Healthcare GP III, LLC, Cormorant Private Healthcare Fund V, LP, Cormorant Private Healthcare GP V, LLC, Cormorant Private Healthcare Fund VI, LP, Cormorant Private Healthcare GP VI, LLC, Cormorant Asset Management, LP and Bihua Chen (collectively, the “Filers”).

Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13D and/or 13G with respect to Common Stock of BlossomHill Therapeutics, Inc. beneficially owned by them from time to time.

Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file a single statement on Schedule 13D and/or 13G (and any amendments thereto) on behalf of each of the Filers, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule.

This Joint Filing Agreement may be terminated by any of the Filers upon written notice or such lesser period of notice as the Filers may mutually agree.

Executed and delivered as of the date first above written.

CORMORANT GLOBAL HEALTHCARE MASTER
FUND, LP

By: Cormorant Global Healthcare GP, LLC
its General Partner

By: /s/ Bihua Chen
Bihua Chen, Managing Member

CORMORANT GLOBAL HEALTHCARE GP, LLC

By: /s/ Bihua Chen
Bihua Chen, Managing Member

CORMORANT PRIVATE HEALTHCARE FUND III, LP

By: Cormorant Private Healthcare GP III, LLC
its General Partner

By: /s/ Bihua Chen
Bihua Chen, Managing Member

CORMORANT PRIVATE HEALTHCARE GP III, LLC

By: /s/ Bihua Chen
Bihua Chen, Managing Member

CORMORANT PRIVATE HEALTHCARE FUND V, LP

By: Cormorant Private Healthcare GP V, LLC
its General Partner

By: /s/ Bihua Chen
Bihua Chen, Managing Member

CORMORANT PRIVATE HEALTHCARE GP V, LLC

By: /s/ Bihua Chen
Bihua Chen, Managing Member

CORMORANT PRIVATE HEALTHCARE FUND VI, LP

By: Cormorant Private Healthcare GP VI, LLC
its General Partner

By: /s/ Bihua Chen
Bihua Chen, Managing Member

CORMORANT PRIVATE HEALTHCARE GP VI, LLC

By: /s/ Bihua Chen
Bihua Chen, Managing Member

CORMORANT ASSET MANAGEMENT, LP

By: Cormorant Asset Management GP, LLC
its General Partner

By: /s/ Bihua Chen
Bihua Chen, Managing Member

/s/ Bihua Chen
Bihua Chen